权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Novel Ruthenium Antimicrobial Platform Technology - Preventing and Treating Multi-Drug Resistant Infections

新型钌抗菌平台技术——预防和治疗多重耐药感染

基本信息

批准号：
10050214
负责人：
金额：
$ 6.37万
依托单位：
METALLOBIO LIMITED
依托单位国家：
英国
项目类别：
Grant for R&D
财政年份：
2023
资助国家：
英国
起止时间：
2023 至无数据
项目状态：
未结题

来源：
https://gtr.ukri.org/projects?ref=10050214
关键词：
Novel Ruthenium Antimicrobial Platform Technology

项目摘要

MetalloBio is a University of Sheffield spin-out company co-founded by Dr Kirsty Smitten and Professor Jim Thomas. MetalloBio are developing a new series of antimicrobial compounds. The compounds are being developed as drugs to treat respiratory bacterial infections and as medical device coatings to prevent infections from developing at the medical device site.The compounds that underpin the platform are more active than current antibiotics, have a novel mechanism of action, little-to-no emergence of resistance and represent a new antimicrobial class. To put this into perspective a new antimicrobial class has not reached the clinic in over 30-years. The antimicrobial is in the preclinical stage of development and the coating technology prototype has been developed.This award accelerate MetalloBio's technology's development and reduce the time to the market, where maximum impact through improved patient quality of life and reduced death rates will be achieved. The project will allow MetalloBio to complete key preclinical experiments outlined by potential customers as essential, including a wide antimicrobial screen of 90 bacterial strains relevant to respiratory infections. Additionally, it will allow the team to scale the synthesis of the antimicrobials to a level that will allow incorporation into polymers for commercial applications. Finally, commercial validity will be studied with a top 10 medical device company, to determine if the polymer can be used to coat their medical device technology's.

MetalloBio是谢菲尔德大学的一家分拆公司，由Kirsty Smitten博士和Jim托马斯教授共同创立。MetalloBio正在开发一系列新的抗菌化合物。这些化合物正在开发为治疗呼吸道细菌感染的药物，以及预防医疗器械现场发生感染的医疗器械涂层。该平台的基础化合物比当前的抗生素更活性，具有新颖的作用机制，很少甚至没有出现耐药性，代表了一种新的抗菌药物类别。从这个角度来看，一种新的抗菌剂已经有30多年没有进入临床了。该抗菌剂正处于临床前开发阶段，涂层技术原型已经开发完成。该奖项加速了MetalloBio的技术开发，缩短了上市时间，通过改善患者生活质量和降低死亡率来实现最大影响。该项目将使MetalloBio能够完成潜在客户认为必不可少的关键临床前实验，包括对90种与呼吸道感染相关的细菌菌株进行广泛的抗菌筛选。此外，它将使团队能够将抗菌剂的合成规模扩大到允许掺入商业应用的聚合物的水平。最后，将与十大医疗器械公司一起研究商业有效性，以确定聚合物是否可用于涂覆其医疗器械技术。